Jill Wu, an analyst from CMB International Securities, maintained the Buy rating on Jiangxi Rimag Group Co., Ltd. Class H (2522 – Research Report). The associated price target is HK$52.39.
Jill Wu has given her Buy rating due to a combination of factors that highlight Jiangxi Rimag Group Co., Ltd.’s strategic position in the AI-driven healthcare sector. The company’s efforts in standardizing medical imaging data have positioned it as a leader in enhancing AI capabilities within healthcare, particularly with the introduction of the Medical Insurance Imaging Cloud Index plan by the NHSA. This initiative is expected to bolster Rimag’s competitive advantage among regional medical institutions.
Additionally, Rimag’s subsidiary, Medical Image Insights, has developed the MIIA Radiological Foundation Model, which is designed to handle a variety of medical imaging tasks using self-supervised learning. Although this model is not expected to directly generate revenue, it is strategically important for future AI tool development. Furthermore, Rimag’s collaboration with Xunfei Healthcare underscores its potential in AI healthcare applications, enhancing its strategic positioning. These factors, combined with a favorable valuation approach using the PS ratio, support the Buy rating with a target price of HK$52.39.
Questions or Comments about the article? Write to editor@tipranks.com